Pfizer may divest consumer healthcare business
Pfizer is looking at spinning off or selling its consumer healthcare business. The global drugs manufacturer said it wants to unlock the value of the business at a time when market valuations are attractive.
Pfizer is looking at spinning off or selling its consumer healthcare business. The global drugs manufacturer said it wants to unlock the value of the business at a time when market valuations are attractive.
Pfizer Consumer Healthcare (PCH) ranks as the world's second-largest consumer healthcare business and includes established brands such as Listerine, Nicorette, Sudafed and Zantac 75. It performed well in 2005 with sales rising by 10% to $3.88bn, (Euro 3.24bn) around 7.5% of Pfizer's overall $51.3bn sales last year. Pfizer's overall revenue fell 2.3% on the previous year, due in part, it said, to competition from cheaper generics.
The company said more details on its strategy will be announced at its 10 February meeting with analysts.